Tell us: what have you never quite understood about weight loss drugs?
Weight loss drugs like Ozempic, Wegovy and Mounjaro have burst into public awareness over the last few years, promising dramatic results and stirring up big questions.
Originally developed for diabetes, these medications are now being prescribed for weight management. But the science, ethics, and long-term effects of these drugs are still being explored.
In a new video series on our It's Complicated Youtube channel, we're investigating the major questions behind some of today's most confusing topics – and weight loss drugs are at the top of that list.
What do these medications actually do to the body? Who should take them, and who decides? Are they reshaping how we think about obesity, health, and personal responsibility? We'll be speaking with experts to better understand the science and the social impact, and we want to make sure we're answering the questions you have.
What have you never quite understood about weight loss drugs? Maybe you're unsure how they work, or you're curious about side effects, access, or stigma. Maybe you've tried them, are thinking about it, or feel overwhelmed by the hype. Whatever your question, we'd love to hear from you. Fill out the form below to share your thoughts. Your questions could help shape our reporting and be featured in the show.
You can tell us what you would like to know about weight-loss drugs by filling in the form below.
Please include as much detail as possible.
Please note, the maximum file size is 5.7 MB.
Your contact details are helpful so we can contact you for more information. They will only be seen by the Guardian.
Your contact details are helpful so we can contact you for more information. They will only be seen by the Guardian.
If you include other people's names please ask them first.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
2 hours ago
- Daily Mail
Fat jabs 'may stop hormone replacement therapy working and raise cancer risk'
Weight-loss drugs could prevent hormone replacement therapy from working – and put the health of menopausal women at risk. The British Menopause Society (BMS) has advised doctors to closely monitor patients taking HRT for menopause while also using fat jabs such as Mounjaro, Wegovy and Ozempic. Experts say the drugs' ability to delay food's transit through the gut can slow absorption of oral pills. The medicines regulator last week warned that women using fat jabs should not rely on oral contraception after receiving more than 40 reports of pregnancies from those using the two drugs together. Now guidance suggests women taking HRT orally should also be aware of the risks. The most common form of HRT is a progesterone pill alongside a skin patch or gel to deliver oestrogen. Importantly, progesterone balances out the effects of oestrogen, which alone boosts womb lining growth, and can cause 'abnormal cells and cancer '. The BMS, concerned about the potential loss of progesterone's protective effect, has now advised doctors to move women to an intrauterine device, such as a coil, or raise the progesterone dose. Professor Annice Mukherjee, of the society's medical advisory council, who led on the guidance, said an imbalance in hormones, particularly in women with obesity, would put them 'at increased risk of womb cancer'. But she stressed that the biggest risk factor for womb cancer is obesity and so overall the weight-loss jabs were a positive tool to reduce weight and cancer risk. It comes as a GP told the Cheltenham Science Festival patients may need to use fat jabs for life. Professor Graham Easton, who has used them himself, said: 'There's no point in most people taking it for a couple of years and then have the weight bouncing back.' There were 2.6million women taking HRT in 2023/24 in England to help with symptoms of the menopause, which can include hot flushes, night sweats, difficulty sleeping, mood changes, and aches. Meanwhile, more than 1.5million Britons are taking weight-loss jabs, with demand doubling in the past six months. It is not known how many are on both drugs together.
Scottish Sun
5 hours ago
- Scottish Sun
Number of fat jab NHS prescriptions doubles in a year as 73% of Sun readers now think about using injections
Prescriptions for Mounjaro surged to 1.1million from just 3,300 a year earlier FAT JAB BRITAIN Number of fat jab NHS prescriptions doubles in a year as 73% of Sun readers now think about using injections Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) ENGLAND has become a fat jab nation as weight loss drug prescriptions double to almost three million in a year. Demand for drugs such as Ozempic and Mounjaro show no signs of slowing, with the NHS splashing out £269million on them in 2024-25. Sign up for Scottish Sun newsletter Sign up 5 Weight loss drug prescriptions in England have doubled to almost three million in a year Credit: Getty 5 Prescriptions for Mounjaro surged to 1.1million from just 3,300 a year earlier Credit: Alamy It comes as a new Sun survey reveals 73 per cent of our readers are thinking of using them as they struggle to shift weight. Official figures show prescriptions for the big three — Ozempic, Mounjaro and Wegovy — rocketed from 1.4million in 2023-24 to 2.7million last year. The increase was driven by Mounjaro, regarded as the strongest jab, with prescriptions surging to 1.1million from just 3,300 a year earlier. Most were prescribed to people with type 2 diabetes, as the injections were designed to treat that condition, and have only recently been approved for weight loss alone. NHS figures suggest prescriptions in Wales also doubled last year, from approximately 34,000 to 70,000, and in Scotland from 40,000 to 50,000. The numbers are expected to rise again this year as the NHS introduces them through slimming clinics. More than a million people are also already buying the jabs privately. Dr Leyla Hannbeck, of the Independent Pharmacies Association, said: 'Never in my career have I seen a product with as much hype as these injections. 'The demand is absolutely huge and I expect it to keep increasing — the only way is up.' Clare Butler, 48, said the jabs also helped her mental health. Weight Loss Jabs - Pros vs Cons The mum, from Manchester, who has lost 4st 4lb, said: 'Mounjaro didn't only quieten the food noise, but it helped quieten the over-thinking, anxious thoughts that had consumed my life for so long.' She described it as, 'the best decision I've ever made for myself'. Research is revealing wide-ranging health benefits to the jabs, such as lowering risks of cancer, heart disease and dementia, yet warnings over weight loss drugs are also increasing. 5 Medics warn they must not be used in pregnancy, while trying to conceive or while breastfeeding, for fear they could lead to miscarriage or birth defects. They have also warned that rapid weight loss caused by the drugs could lead to bone loss and osteoporosis. Annual statistics from the NHS Business Services Authority show the total number of GLP-1 injections prescribed increased from 1,427,968 in the 2023-24 financial year to 2,734,499 in 2024-25. It was a 91 per cent spike — accounted for almost entirely by Mounjaro's growth. 5 Clare Butler lost 4st4lb on Mounjaro Credit: Clare Butler 5 Clare said the jabs not only helped her lose weight but improved her mental health Credit: Clare Butler The totals also included brands such as Saxenda, Ozempic and Wegovy. In the same period, the cost of prescribing rose from £137,808,297 to £269,276,366 — equal to 2.4 per cent of all NHS spending on pharmacy medicines, or £1 in every £42. The NHS said: 'We expect demand for weight loss drugs to continue to rise in the coming years.' The Department of Health added: 'We recognise the drugs' importance for treating type 2 diabetes and their exciting remit as new treatments for obesity.' Unlock even more award-winning articles as The Sun launches brand new membership programme - Sun Club.
The Sun
5 hours ago
- The Sun
Number of fat jab NHS prescriptions doubles in a year as 73% of Sun readers now think about using injections
ENGLAND has become a fat jab nation as weight loss drug prescriptions double to almost three million in a year. Demand for drugs such as Ozempic and Mounjaro show no signs of slowing, with the NHS splashing out £269million on them in 2024-25. 5 It comes as a new Sun survey reveals 73 per cent of our readers are thinking of using them as they struggle to shift weight. Official figures show prescriptions for the big three — Ozempic, Mounjaro and Wegovy — rocketed from 1.4million in 2023-24 to 2.7million last year. The increase was driven by Mounjaro, regarded as the strongest jab, with prescriptions surging to 1.1million from just 3,300 a year earlier. Most were prescribed to people with type 2 diabetes, as the injections were designed to treat that condition, and have only recently been approved for weight loss alone. NHS figures suggest prescriptions in Wales also doubled last year, from approximately 34,000 to 70,000, and in Scotland from 40,000 to 50,000. The numbers are expected to rise again this year as the NHS introduces them through slimming clinics. More than a million people are also already buying the jabs privately. Dr Leyla Hannbeck, of the Independent Pharmacies Association, said: 'Never in my career have I seen a product with as much hype as these injections. 'The demand is absolutely huge and I expect it to keep increasing — the only way is up.' Clare Butler, 48, said the jabs also helped her mental health. Weight Loss Jabs - Pros vs Cons The mum, from Manchester, who has lost 4st 4lb, said: 'Mounjaro didn't only quieten the food noise, but it helped quieten the over-thinking, anxious thoughts that had consumed my life for so long.' She described it as, 'the best decision I've ever made for myself'. Research is revealing wide-ranging health benefits to the jabs, such as lowering risks of cancer, heart disease and dementia, yet warnings over weight loss drugs are also increasing. 5 Medics warn they must not be used in pregnancy, while trying to conceive or while breastfeeding, for fear they could lead to miscarriage or birth defects. They have also warned that rapid weight loss caused by the drugs could lead to bone loss and osteoporosis. Annual statistics from the NHS Business Services Authority show the total number of GLP-1 injections prescribed increased from 1,427,968 in the 2023-24 financial year to 2,734,499 in 2024-25. It was a 91 per cent spike — accounted for almost entirely by Mounjaro's growth. 5 5 The totals also included brands such as Saxenda, Ozempic and Wegovy. In the same period, the cost of prescribing rose from £137,808,297 to £269,276,366 — equal to 2.4 per cent of all NHS spending on pharmacy medicines, or £1 in every £42. The NHS said: 'We expect demand for weight loss drugs to continue to rise in the coming years.' The Department of Health added: 'We recognise the drugs' importance for treating type 2 diabetes and their exciting remit as new treatments for obesity.'
